Pacific Biosciences CFO reports $2.05m stock sale

Pacific Biosciences of California CFO James R Gibson II disclosed the sale of 661,815 shares of company stock worth $2.05 million on October 6, 2026. The trades occurred under a pre-existing Rule 10b5-1 trading plan, with individual shares selling for prices ranging from $3.00 to $3.33, compared to the CFO's average sale price of $3.108 per share.

Despite the drop in the stock's price to $2.33, it has risen 64% year-over-year. Prior to the stock sale, Gibson exercised options to purchase an additional 500,000 shares at $1.18 per share, totaling $590,000. These options were part of an award that began vesting one year after granting with the remaining shares vesting monthly over the following three years, subject to continued employment.

Following these transactions, Gibson now directly owns 1,083,848 shares of Pacific Biosciences common stock, in addition to 1,500,000 derivative securities in the form of stock options. Analysts predict PACB to be overvalued at its current price. The company's financials reported a second-quarter 2026 revenue of $39.0 million, missing the forecasted $40.69 million and resulting in an adjusted loss of $0.14 per share.

The company has lowered its full-year guidance, predicting cash flow breakeven to occur later than anticipated.